Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 4Gastrointestinal 2Thoracic 1Sarcoma 1Other solid neoplasm 1Lymphoid 1

Conditions

Neoplasm Metastasis 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 6belinostat 2Pemetrexed 2Cyclophosphamide 2Cisplatin 2Carboplatin 2tocilizumab 1sargramostim 1ribociclib 1rebastinib 1enzalutamide 1entinostat 1durvalumab 1cemiplimab 1avelumab 1atezolizumab 1abemaciclib 1Valacyclovir 1Surgical Procedures, Operative 1Sorafenib 1Sirolimus 1Quality of Life 1Psychiatric Rehabilitation 1Polymerase Chain Reaction 1Plicamycin 1Patient Reported Outcome Measures 1Nivolumab 1Molecular Diagnostic Techniques 1Midazolam 1Microarray Analysis 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × LY3023414 × Other solid neoplasm × Clear all
NCT01655225 2022-04-08

A Study of LY3023414 in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
156 enrolled
BreastLymphoidOther solid neoplasmThoracic

Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lymphoma, Lymphoma, Non-Hodgkin, Mesothelioma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡